Baker Bros. Advisors LP Summit Therapeutics Inc. Transaction History
Baker Bros. Advisors LP
- $12.3 Billion
- Q3 2025
A detailed history of Baker Bros. Advisors LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 33,722,974 shares of SMMT stock, worth $615 Million. This represents 5.7% of its overall portfolio holdings.
Number of Shares
33,722,974
Previous 33,722,974
-0.0%
Holding current value
$615 Million
Previous $718 Million
2.58%
% of portfolio
5.7%
Previous 7.27%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
267Shares Held
94.2MCall Options Held
4.72MPut Options Held
4.03M-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.13MShares$57.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...